Item Type | Name |
Concept
|
Antigens, Neoplasm
|
Concept
|
Antigens, Viral, Tumor
|
Concept
|
Bone Neoplasms
|
Concept
|
Breast Neoplasms
|
Concept
|
Cell Fusion
|
Concept
|
Colonic Neoplasms
|
Concept
|
DNA, Neoplasm
|
Concept
|
Esophageal Neoplasms
|
Concept
|
Head and Neck Neoplasms
|
Concept
|
Intestinal Neoplasms
|
Concept
|
Jejunal Neoplasms
|
Concept
|
Kidney Neoplasms
|
Concept
|
Neoplasm Invasiveness
|
Concept
|
Neoplasm Metastasis
|
Concept
|
Neoplasm Proteins
|
Concept
|
Neoplasm Recurrence, Local
|
Concept
|
Neoplasm Staging
|
Concept
|
Neoplasm Transplantation
|
Concept
|
Neoplasms
|
Concept
|
Neoplasms, Experimental
|
Concept
|
Neoplasms, Glandular and Epithelial
|
Concept
|
RNA, Neoplasm
|
Concept
|
Spinal Neoplasms
|
Concept
|
Tumor Cells, Cultured
|
Concept
|
Biomarkers, Tumor
|
Concept
|
Tumor Necrosis Factor-alpha
|
Concept
|
Tumor Virus Infections
|
Concept
|
Colorectal Neoplasms
|
Concept
|
Tumor Lysis Syndrome
|
Concept
|
Genes, Tumor Suppressor
|
Concept
|
Tumor Suppressor Protein p53
|
Concept
|
Neoplasms, Second Primary
|
Concept
|
Endometrial Neoplasms
|
Concept
|
Receptors, Tumor Necrosis Factor
|
Concept
|
Neoplasm, Residual
|
Concept
|
Drug Resistance, Neoplasm
|
Concept
|
Bone Marrow Neoplasms
|
Concept
|
Hematologic Neoplasms
|
Concept
|
Graft vs Tumor Effect
|
Concept
|
Tumor Suppressor Proteins
|
Concept
|
Cell Line, Tumor
|
Concept
|
Tumor Burden
|
Concept
|
Genes, Neoplasm
|
Concept
|
Tumor Necrosis Factor Ligand Superfamily Member 13
|
Concept
|
Neoplasms, Plasma Cell
|
Concept
|
Tumor Microenvironment
|
Concept
|
Neoplasm Grading
|
Academic Article
|
Mast cells in Waldenstrom''s macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling.
|
Academic Article
|
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.
|
Academic Article
|
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström''s macroglobulinemia.
|
Academic Article
|
MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.
|
Academic Article
|
The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.
|
Academic Article
|
miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth.
|
Academic Article
|
Deficiency of the immunostimulatory cytokine IL-21 promotes intestinal neoplasia via dysregulation of the Th1/Th17 axis.
|
Academic Article
|
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
|
Academic Article
|
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
|
Academic Article
|
Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.
|
Academic Article
|
In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2''-deacetyl-N2''-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
|
Academic Article
|
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.
|
Academic Article
|
Antimyeloma activity of heat shock protein-90 inhibition.
|
Academic Article
|
Anti-tumor activities of selective HSP90a/ß inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
|
Academic Article
|
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.
|
Academic Article
|
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3''-kinase/AKT signaling.
|
Academic Article
|
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
|
Academic Article
|
Biology and therapy of multiple myeloma in 1996.
|
Academic Article
|
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
|
Academic Article
|
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
|
Academic Article
|
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
|
Academic Article
|
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
|
Academic Article
|
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.
|
Academic Article
|
The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.
|
Academic Article
|
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.
|
Academic Article
|
In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.
|
Academic Article
|
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.
|
Academic Article
|
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
|
Academic Article
|
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.
|
Academic Article
|
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).
|
Academic Article
|
Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma.
|
Academic Article
|
Podocyte injury associated glomerulopathies induced by pamidronate.
|
Academic Article
|
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
|
Academic Article
|
Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications.
|
Academic Article
|
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing.
|
Academic Article
|
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
|
Academic Article
|
FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma.
|
Academic Article
|
The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease.
|
Academic Article
|
Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
|
Academic Article
|
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
|
Academic Article
|
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.
|
Academic Article
|
Clinical activity of arsenic trioxide for the treatment of multiple myeloma.
|
Academic Article
|
Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors.
|
Academic Article
|
Genomic evolution in Barrett''s adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome.
|
Academic Article
|
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
|
Academic Article
|
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
|
Academic Article
|
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
|
Academic Article
|
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
|
Academic Article
|
Nucleotide excision repair is a potential therapeutic target in multiple myeloma.
|
Academic Article
|
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
|
Academic Article
|
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
|
Academic Article
|
Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis.
|
Academic Article
|
Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma.
|
Academic Article
|
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.
|
Academic Article
|
Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma.
|
Academic Article
|
Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells.
|
Academic Article
|
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.
|
Academic Article
|
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
|
Academic Article
|
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
|
Academic Article
|
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.
|
Academic Article
|
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
|
Academic Article
|
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
|
Academic Article
|
MRI features of extramedullary myeloma.
|
Academic Article
|
Interaction of adeno-associated virus Rep78 with p53: implications in growth inhibition.
|
Academic Article
|
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.
|
Academic Article
|
Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi''s sarcoma cells.
|
Academic Article
|
Targeting homologous recombination and telomerase in Barrett''s adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth.
|
Academic Article
|
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.
|
Academic Article
|
Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma.
|
Academic Article
|
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
|
Academic Article
|
Deficiency of IL-17A, but not the prototypical Th17 transcription factor ROR?t, decreases murine spontaneous intestinal tumorigenesis.
|
Academic Article
|
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells.
|
Academic Article
|
Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome.
|
Academic Article
|
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
|
Academic Article
|
Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome.
|
Academic Article
|
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
|
Academic Article
|
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells.
|
Academic Article
|
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.
|
Academic Article
|
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
|
Academic Article
|
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
|
Academic Article
|
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.
|
Academic Article
|
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
|
Academic Article
|
Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
|
Academic Article
|
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.
|
Academic Article
|
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.
|
Academic Article
|
Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein.
|
Academic Article
|
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
|
Academic Article
|
Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy.
|
Academic Article
|
Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function.
|
Academic Article
|
Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model.
|
Academic Article
|
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
|
Academic Article
|
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
|
Academic Article
|
Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.
|
Academic Article
|
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
|
Academic Article
|
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs.
|
Academic Article
|
A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.
|
Academic Article
|
Dichloroacetate induces apoptosis in endometrial cancer cells.
|
Academic Article
|
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.
|
Academic Article
|
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells.
|
Academic Article
|
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
|
Academic Article
|
Blockade of XBP1 splicing by inhibition of IRE1a is a promising therapeutic option in multiple myeloma.
|
Academic Article
|
A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy.
|
Academic Article
|
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
|
Academic Article
|
Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma.
|
Academic Article
|
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
|
Academic Article
|
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
|
Academic Article
|
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
|
Academic Article
|
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.
|
Academic Article
|
Minor clone provides a reservoir for relapse in multiple myeloma.
|
Academic Article
|
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.
|
Academic Article
|
Deep Response in Multiple Myeloma: A Critical Review.
|
Academic Article
|
CCR6, the sole receptor for the chemokine CCL20, promotes spontaneous intestinal tumorigenesis.
|
Academic Article
|
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma.
|
Academic Article
|
miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/ß-catenin/BCL9 pathway.
|
Academic Article
|
Focus on multiple myeloma.
|
Academic Article
|
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
|
Academic Article
|
Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.
|
Academic Article
|
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
|
Academic Article
|
Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
|
Academic Article
|
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.
|
Academic Article
|
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.
|
Academic Article
|
Expression of AAV Rep proteins in SV40-transformed and untransformed cells: reciprocal interaction with host DNA synthesis.
|
Academic Article
|
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.
|
Academic Article
|
14-3-3? binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors.
|
Academic Article
|
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
|
Academic Article
|
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.
|
Academic Article
|
Dual level inhibition of E2F-1 activity by adeno-associated virus Rep78.
|
Academic Article
|
Stromal CCR6 drives tumor growth in a murine transplantable colon cancer through recruitment of tumor-promoting macrophages.
|
Academic Article
|
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
|
Academic Article
|
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
|
Academic Article
|
Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.
|
Academic Article
|
Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.
|
Academic Article
|
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
|
Academic Article
|
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.
|
Academic Article
|
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
|
Academic Article
|
A clinically relevant SCID-hu in vivo model of human multiple myeloma.
|
Academic Article
|
Differential and limited expression of mutant alleles in multiple myeloma.
|
Academic Article
|
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
|
Academic Article
|
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
|
Academic Article
|
In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.
|
Academic Article
|
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
|
Academic Article
|
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
|
Academic Article
|
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
|
Academic Article
|
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.
|
Academic Article
|
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.
|
Academic Article
|
canEvolve: a web portal for integrative oncogenomics.
|
Academic Article
|
Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.
|
Academic Article
|
Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.
|
Academic Article
|
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
|
Academic Article
|
Minimal residual disease in multiple myeloma.
|
Academic Article
|
Pyk2 promotes tumor progression in multiple myeloma.
|
Academic Article
|
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
|
Academic Article
|
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.
|
Academic Article
|
Lymphomatoid granulomatosis following autologous stem cell transplantation.
|
Academic Article
|
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
|
Academic Article
|
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
|
Academic Article
|
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.
|
Academic Article
|
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
|
Academic Article
|
JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells.
|
Academic Article
|
Plasma cell disorders: an historical perspective.
|
Academic Article
|
Investigative tools for diagnosis and management.
|
Academic Article
|
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
|
Academic Article
|
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
|
Academic Article
|
Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws?
|
Academic Article
|
A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications.
|
Academic Article
|
A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.
|
Academic Article
|
Telomerase inhibitors as anticancer therapy.
|
Academic Article
|
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.
|
Academic Article
|
Cytokines modulate telomerase activity in a human multiple myeloma cell line.
|
Academic Article
|
Targeting PI3K and RAD51 in Barrett''s adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth.
|
Academic Article
|
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
|
Academic Article
|
Kaposi''s sarcoma-associated herpesvirus-encoded G protein-coupled receptor activation of c-jun amino-terminal kinase/stress-activated protein kinase and lyn kinase is mediated by related adhesion focal tyrosine kinase/proline-rich tyrosine kinase 2.
|
Academic Article
|
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
|
Academic Article
|
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
|
Academic Article
|
Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma.
|
Academic Article
|
Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.
|
Academic Article
|
Combination of a Selective HSP90a/ß Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.
|
Academic Article
|
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
|
Academic Article
|
Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.
|
Academic Article
|
A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma.
|
Academic Article
|
Genomic patterns of progression in smoldering multiple myeloma.
|
Academic Article
|
APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.
|
Academic Article
|
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.
|
Academic Article
|
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.
|
Academic Article
|
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.
|
Academic Article
|
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
|
Academic Article
|
Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.
|
Academic Article
|
Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.
|
Academic Article
|
Immunotherapy for multiple myeloma.
|
Academic Article
|
Reply to M. Roschewski et al.
|
Academic Article
|
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
|
Academic Article
|
Growth arrest, apoptosis, and telomere shortening of Barrett''s-associated adenocarcinoma cells by a telomerase inhibitor.
|
Academic Article
|
Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.
|
Academic Article
|
Role of apurinic/apyrimidinic nucleases in the regulation of homologous recombination in myeloma: mechanisms and translational significance.
|
Academic Article
|
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
|
Academic Article
|
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.
|
Academic Article
|
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.
|
Academic Article
|
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
|
Academic Article
|
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
|
Academic Article
|
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens.
|
Academic Article
|
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
|
Academic Article
|
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.
|
Academic Article
|
Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.
|
Academic Article
|
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.
|
Academic Article
|
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
|
Academic Article
|
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.
|
Academic Article
|
Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells.
|
Academic Article
|
The shaping and functional consequences of the dosage effect landscape in multiple myeloma.
|
Academic Article
|
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
|
Academic Article
|
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.
|
Academic Article
|
Biology of telomeres: importance in etiology of esophageal cancer and as therapeutic target.
|
Academic Article
|
Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma.
|
Academic Article
|
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
|
Academic Article
|
Significant biological role of sp1 transactivation in multiple myeloma.
|
Academic Article
|
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.
|
Academic Article
|
Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
|
Academic Article
|
Effects of oligonucleotide N3''-->P5'' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.
|
Academic Article
|
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
|
Academic Article
|
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.
|
Academic Article
|
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
|
Academic Article
|
Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
|
Academic Article
|
CSNK1a1 mediates malignant plasma cell survival.
|
Academic Article
|
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.
|
Academic Article
|
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.
|
Academic Article
|
Myeloma Minimal Residual Disease and Surrogacy-Reply.
|
Academic Article
|
Telomere maintenance in laser capture microdissection-purified Barrett''s adenocarcinoma cells and effect of telomerase inhibition in vivo.
|
Academic Article
|
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
|
Academic Article
|
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
|
Academic Article
|
NF-kappa B as a therapeutic target in multiple myeloma.
|
Academic Article
|
DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.
|
Academic Article
|
Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
|
Academic Article
|
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
|
Academic Article
|
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.
|
Academic Article
|
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.
|
Academic Article
|
Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.
|
Academic Article
|
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
|
Academic Article
|
Immunotherapy strategies in multiple myeloma.
|
Academic Article
|
Solitary Extramedullary Multiple Myeloma Presenting with Small Bowel Obstruction.
|
Academic Article
|
A SCID-hu in vivo model of human Waldenström macroglobulinemia.
|
Academic Article
|
Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
|
Academic Article
|
Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells.
|
Academic Article
|
c-Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi''s sarcoma cells.
|
Academic Article
|
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
|
Academic Article
|
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
|
Academic Article
|
Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.
|
Academic Article
|
Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
|
Academic Article
|
Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein.
|
Academic Article
|
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
|
Academic Article
|
An ikaros-containing chromatin-remodeling complex in adult-type erythroid cells.
|
Academic Article
|
Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.
|
Academic Article
|
Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation.
|
Academic Article
|
The architectural transcription factor high mobility group I(Y) participates in photoreceptor-specific gene expression.
|
Academic Article
|
MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma.
|
Academic Article
|
Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.
|
Academic Article
|
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells.
|
Academic Article
|
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.
|
Academic Article
|
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.
|
Academic Article
|
Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients.
|
Academic Article
|
Intracellular NAD? depletion enhances bortezomib-induced anti-myeloma activity.
|
Academic Article
|
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
|
Academic Article
|
Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir.
|
Academic Article
|
Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches.
|
Academic Article
|
Targeted disruption of the BCL9/ß-catenin complex inhibits oncogenic Wnt signaling.
|
Academic Article
|
Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance.
|
Academic Article
|
DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
|
Academic Article
|
The dChip survival analysis module for microarray data.
|
Academic Article
|
Multiple myeloma clonal evolution in homogeneously treated patients.
|
Academic Article
|
Genomic landscape and chronological reconstruction of driver events in multiple myeloma.
|
Academic Article
|
A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.
|
Academic Article
|
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.
|
Academic Article
|
Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma.
|
Academic Article
|
Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.
|
Academic Article
|
A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma.
|
Academic Article
|
Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease.
|
Academic Article
|
Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
|
Academic Article
|
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.
|